Windtree Therapeutics, Inc. (WINT)
NASDAQ: WINT · Real-Time Price · USD
1.200
-0.060 (-4.76%)
At close: Apr 1, 2025, 4:00 PM
1.230
+0.030 (2.47%)
After-hours: Apr 1, 2025, 5:00 PM EDT
Windtree Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
899.21K
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
WINT News
- 6 days ago - Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics - PRNewsWire
- 8 days ago - Evofem Reports Fourth Consecutive Year of Net Sales Growth - PRNewsWire
- 8 days ago - Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - GlobeNewsWire
- 12 days ago - Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product - GlobeNewsWire
- 2 months ago - Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline - GlobeNewsWire
- 2 months ago - Windtree Announces the Addition of Leanne Kelly to Its Board of Directors - GlobeNewsWire
- 4 months ago - Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia - GlobeNewsWire
- 4 months ago - Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction - GlobeNewsWire